Clomid (clomiphene) is the fertility pill most people have heard of. Letrozole is a breast-cancer medicine that fertility specialists increasingly choose first for women who do not ovulate regularly. The reason is mostly about live-birth results in PCOS, and the catch is that the use is off label in the United States.
For women with PCOS who are not ovulating and have no other infertility factors, the 2023 international PCOS guideline recommends letrozole rather than clomiphene as the first-line medicine. Clomiphene is the drug whose U.S. label covers ovulatory dysfunction; letrozole’s FDA label covers breast cancer in postmenopausal women. Neither choice is a self-service decision: both need pregnancy exclusion, a plan for monitoring and a clear stopping point.
You sit down expecting to hear “Clomid” and your reproductive endocrinologist or OB-GYN says “letrozole” instead. A quick search turns up the Femara package insert, which says nothing about pregnancy attempts and a lot about breast cancer. That mismatch is the single most common source of worry, so it is worth answering first.
What each label actually covers
The current clomiphene citrate tablet label on DailyMed states that the drug “is indicated for the treatment of ovulatory dysfunction in women desiring pregnancy.” It also says impediments to pregnancy must be excluded or adequately treated first, and that long-term cyclic therapy is not recommended beyond a total of about six cycles.
The Femara (letrozole) label on DailyMed lists indications for early and advanced hormone receptor positive breast cancer in postmenopausal women. It also says Femara “can cause fetal harm and is contraindicated for use in pregnant women,” and advises a pregnancy test before treatment in females of reproductive potential. Using it to trigger ovulation is a practice that clinicians adopted from research; the label does not describe it.
That is what “off label” means here. It is legal and common in medicine, and the 2023 guideline itself notes that ovulation-induction agents, including letrozole, metformin and clomiphene citrate, are off label in many countries and that clinicians should discuss the evidence and side effects with patients. An American Family Physician evidence summary likewise advises counseling women that this use remains off label in both the U.S. and Canada.
Why guidelines now put letrozole first
The 2023 International Evidence-based Guideline for PCOS says letrozole “should be the first-line pharmacological treatment for ovulation induction in infertile anovulatory women with PCOS, with no other infertility factors.” A separate recommendation says letrozole should be used rather than clomiphene “to improve ovulation, clinical pregnancy, and live birth rates.” The guideline grades the certainty of that head-to-head comparison lower than its wording suggests, so the recommendation is firm but the data are not unlimited.
The numbers behind it come from trials such as those pooled in a Cochrane review. In the AAFP summary of that review, letrozole produced about 314 live births per 1,000 women compared with 214 per 1,000 for clomiphene, with a number needed to treat of 10 and evidence rated moderate. Miscarriage was similar (191 versus 201 per 1,000, not a significant difference), and ovarian hyperstimulation syndrome was 5 per 1,000 in both groups.
| Question | Clomiphene (Clomid) | Letrozole |
|---|---|---|
| FDA-labeled use | Ovulatory dysfunction in women who want to become pregnant | Breast cancer in postmenopausal women; ovulation induction is off label |
| Drug class | Selective estrogen receptor modulator; acts on estrogen-receptor feedback | Aromatase inhibitor; lowers estrogen production |
| 2023 PCOS guideline position | Acceptable; may be used instead of metformin alone; often combined with metformin | Preferred first-line medicine when anovulation is the only infertility factor |
| Live birth in the pooled trials summarized by AAFP | About 214 per 1,000 | About 314 per 1,000 |
| Label cautions to know | Visual symptoms, ovarian enlargement and OHSS, multiple pregnancy | Fetal harm if taken in pregnancy, so pregnancy is excluded first; bone density effects in cancer-treatment use |
Side effects and risks you will hear about
Clomiphene carries the more detailed fertility-specific warnings because it is the labeled drug. The clinical-trial table in the label lists ovarian enlargement in 13.6% of patients, vasomotor flushes in 10.4%, abdominal or pelvic discomfort and bloating in 5.5%, nausea and vomiting in 2.2%, and visual symptoms in 1.5%. The label tells patients with any visual symptoms to stop treatment and have a complete eye examination promptly. For a longer walk-through, see our guides to Clomid side effects and to vision changes on Clomid.
The label also reports that among the pregnancies recorded in its clinical studies, multiple pregnancies occurred in 7.98% (6.9% twins). The AAFP summary of the letrozole comparison found a multiple-pregnancy rate near 1.5% in each group, with no significant difference. In other words, the data summarized there do not show that switching to letrozole removes the risk of twins, and the guideline still treats monitoring as part of clomiphene care, noting that clomiphene cycles may require ultrasound monitoring.
The labels and the guideline point the same direction: confirm that you are not already pregnant before a cycle starts. The 2023 guideline states letrozole should not be given where pregnancy is possible, while adding that the evidence shows no increased fetal-abnormality rate compared with clomiphene or natural conception. The Femara label’s fetal-harm language comes from its use in cancer, in animal studies and in postmarketing reports.
Who the PCOS recommendation does not cover
The guideline wording is narrow on purpose: anovulatory infertility in PCOS, no other infertility factors. It does not say letrozole beats clomiphene for every cause of trouble conceiving, and we could not confirm from the sources we opened what any society recommends for unexplained infertility. If your semen analysis, tubal status or age changes the picture, the best first step may not be an oral ovulation medicine at all. Our overview of ovulation disorders and PCOS explains how the diagnosis is made.
Gonadotropin injections sit one step up. The guideline allows them as second-line therapy after oral agents fail and notes that they carry a higher multiple-pregnancy rate, which is why they come with closer ultrasound monitoring. IVF is the next step after that when other ovulation induction has not worked.
What a treatment plan usually has to include
Whichever medicine is chosen, the guideline and the clomiphene label describe similar scaffolding. The guideline says prenatal vitamin supplementation should begin with ovulation induction, in line with routine preconception care, and that pregnancy should be excluded before treatment. It also recommends that people with PCOS hear how excess weight can affect pregnancy, miscarriage and live-birth rates after infertility treatment, along with attention to blood pressure, smoking, alcohol, sleep and mental health. That list is not a lecture; it is part of the evidence on what improves the odds of a healthy pregnancy.
The clomiphene label adds specific checkpoints that clinicians often carry over to other oral agents: a pelvic examination before the first course and before each later course, a check between cycles for ovarian enlargement or cysts, and a defined stopping point. If ovulation does not occur after three courses, the label says further treatment is not recommended and the patient should be reevaluated; it also advises against long-term cyclic therapy beyond about six cycles in total. Those figures are the clomiphene label’s, not letrozole rules, so ask your prescriber what limit applies to your plan.
One more practical point is how ovulation is confirmed. The label notes that properly timed intercourse in relation to ovulation matters and that a basal body temperature graph or other appropriate tests may help establish whether ovulation occurred. How a given clinic confirms it (charting, hormone tests, ultrasound) is the monitoring conversation worth having before the first cycle rather than after a disappointing one.
Where each option sits in the guideline’s ladder
Seeing the whole sequence makes a letrozole prescription less of a surprise, and shows what happens if it does not work. The table summarizes the 2023 guideline’s recommendations for women with PCOS, anovulatory infertility and no other infertility factors.
| Step | What the guideline says | Worth knowing |
|---|---|---|
| Metformin alone | Could be used, while telling women there are more effective ovulation agents | The guideline notes mild gastrointestinal side effects and lower monitoring and cost burden |
| Clomiphene | Could be used in preference to metformin; clomiphene plus metformin could be used rather than clomiphene alone | Risk of multiple pregnancy is increased, so clomiphene cycles may require ultrasound monitoring |
| Letrozole | First-line; used rather than clomiphene to improve ovulation, clinical pregnancy and live birth rates | Off label in many countries; not given where pregnancy is possible |
| Gonadotropin injections | Second-line after oral agents fail; may be considered first line as an alternative to clomiphene in some women | Higher live birth rate but higher multiple-pregnancy rate; low-dose protocols and close ultrasound monitoring are advised |
| Laparoscopic ovarian surgery | Second-line option when clomiphene has not worked | A procedure with its own risks, discussed separately |
| IVF | Could be offered if first- or second-line ovulation induction has failed, absent an absolute indication for IVF | The guideline stresses counseling on ovarian hyperstimulation risk and favors single embryo transfer |
Three realistic situations
Clomiphene did not trigger ovulation. The clomiphene label says that if ovulation does not occur after three courses of therapy, further treatment is not recommended and the patient should be reevaluated. For women with PCOS who are resistant to clomiphene, the guideline names gonadotropins or laparoscopic ovarian surgery as options after counseling about the higher live birth rate and higher multiple-pregnancy rate with gonadotropins. A switch to letrozole may also be considered, but the guideline’s own list of clomiphene-resistance options does not mention it, so ask the clinician what the plan is and why.
The period is regular and the problem is not ovulation. The ASRM fact sheet notes that oral medicines are sometimes given to women who ovulate on their own but are still not conceiving, to release more than one egg as part of fertility treatment, and that pregnancy rates tend to be lower in women who already ovulate, especially if the medicines are not combined with other treatments like insemination. The PCOS guideline’s letrozole preference does not automatically carry over to this situation.
Weight, age or other factors complicate the picture. The guideline asks that people with PCOS planning pregnancy hear how excess weight affects pregnancy, miscarriage and live birth rates after infertility treatment, and that weight, blood pressure, smoking, alcohol, folate, sleep and mental health be considered. It frames this as part of preparation, not a precondition for being treated, and a clinician can tell you how it applies in your case.
Questions to bring to the appointment
- Is my diagnosis PCOS-related anovulation, and have other factors (semen analysis, tubal patency, age) been checked?
- Why letrozole for me, and is the plan timed intercourse or insemination?
- How will ovulation be confirmed, and will there be ultrasound monitoring? Our page on ovulation induction monitoring lists what monitoring can look like.
- How will pregnancy be excluded before each cycle?
- How many cycles will we try before reassessing?
- Does my insurance treat an off-label prescription differently from Clomid?
The last question is practical, not clinical. Coverage rules vary and the pharmacy may ask the prescriber about the indication. Having the prescriber write the reason into the chart usually answers that.
What we know and what we do not
| Reasonably established | Less certain |
|---|---|
| Guideline-level preference for letrozole in anovulatory PCOS with no other infertility factors | Which drug is better for unexplained infertility or for women without PCOS (not covered in the sources checked) |
| Higher live birth per the pooled trials summarized by AAFP, similar miscarriage and OHSS | Exact live-birth gap for any one patient, which depends on weight, age and other factors |
| Clomiphene remains the on-label medicine and remains acceptable | Long-term outcomes beyond the pregnancy itself, which the guideline says need ongoing monitoring in studies |
A reasonable summary: a letrozole prescription is a mainstream choice rather than an experiment, but it deserves the same ground rules as Clomid, meaning a pregnancy test, a defined number of cycles and a way to check that you are ovulating rather than having a bleed that looks like a period. Whether you take it, how long and when to switch are decisions for the prescriber who is monitoring you.
Sources
- Teede et al., 2023 International Evidence-based Guideline for PCOS (J Clin Endocrinol Metab)
- DailyMed: Clomiphene citrate tablets label
- DailyMed: Femara (letrozole) label
- American Family Physician: Letrozole vs. clomiphene for subfertile women with PCOS
- MedlinePlus: Letrozole
Evidence checked October 30, 2026. General information only; it does not recommend a specific fertility prescription.